Assessing the efficacy of treatments for panic disorder and agoraphobia. I. Methodological problems.

Abstract:

:An assessment of the efficacy of treatments in panic disorder and agoraphobia (PDA) is complicated by methodological problems resulting from the complexity of these disorders. In this paper, commonly used anxiety scales are discussed with regard to their relevance in the assessment of PDA. Although there are already many scales for assessing anxiety and agoraphobia, a qualified instrument for measuring the severity of PDA is still lacking. A survey of the instruments used in recent treatment studies of PDA shows that rather inhomogeneous efficacy criteria were applied. Most often, panic attack frequency was taken as a severity criterion, although this measure showed little power to differentiate between treatments. To deal with the special features of PDA, a battery of different scales was usually employed and non-standardized scales were sometimes used additionally. A new rating scale designed to overcome the methodological problems associated with the assessment of severity in PDA was introduced. The use of the psychiatrist-rated Panic and Agoraphobia (P&A) scale in patients with DSM-III-R panic disorder and/or agoraphobia (n = 235) shows that this scale has the highest correlation with the psychiatrists' clinical global impression of PDA patients (r = 0.79, p < 0.0001), compared with other commonly used observer-rated anxiety scales. The self-rating version of the P&A again had the highest correlation with a patient-rated clinical global impression (r = 0.82, p < 0.0001), whereas the other patient-rated anxiety questionnaires correlated only moderately or poorly. By means of logistic regression, it was shown that the five subscores of the scale contribute independently and almost equally to the prediction of PDA severity.

authors

Bandelow B,Hajak G,Holzrichter S,Kunert HJ,Rüther E

doi

10.1097/00004850-199506000-00004

subject

Has Abstract

pub_date

1995-06-01 00:00:00

pages

83-93

issue

2

eissn

0268-1315

issn

1473-5857

journal_volume

10

pub_type

杂志文章
  • The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.

    abstract::Depression compromises affected individuals' functional well-being and impairs their level of social and workplace performance. Improved social functioning in depressed patients may improve their work productivity. This study evaluated the differential effects of two antidepressants on social functioning outcomes for ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200015050-00005

    authors: Venditti LN,Arcelus A,Birnbaum H,Greenberg P,Barr CE,Rowland C,Williamson T

    更新日期:2000-09-01 00:00:00

  • Adverse effects of antipsychotic drugs.

    abstract::The side effects of antipsychotic drugs have always been a major concern for clinicians and the appreciation of their importance in the treatment of schizophrenia has increased steadily over the years. Epidemiological studies as well as trials of the prevention and treatment of antipsychotic side effects are the conse...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199501005-00005

    authors: Whitworth AB,Fleischhacker WW

    更新日期:1995-01-01 00:00:00

  • Selective serotonin reuptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.

    abstract::The treatment of negative symptoms of schizophrenia presents a major clinical challenge. This review examines the evidence pertaining to the efficacy, tolerability and safety of adding selective serotonin reuptake inhibitors (SSRIs) to antipsychotic agents in the treatment of negative symptoms in schizophrenia. Import...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-200311000-00001

    authors: Silver H

    更新日期:2003-11-01 00:00:00

  • An open-label study of escitalopram in body dysmorphic disorder.

    abstract::Body dysmorphic disorder (BDD) is a relatively common and impairing disorder. Selective serotonin reuptake inhibitors (SRIs) appear selectively efficacious for BDD, but pharmacotherapy research is limited, and escitalopram has not been studied. Fifteen subjects with BDD were treated with escitalopram and assessed with...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.yic.0000194378.65460.ef

    authors: Phillips KA

    更新日期:2006-05-01 00:00:00

  • A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression.

    abstract::Fluvoxamine, a selective serotonin reuptake inhibitor, was investigated in a 6-week double-blind study among severely ill inpatients with DSM-III major depression. All but 1 patient also fulfilled criteria for melancholia. Following a 3-day placebo wash-out patients were randomly assigned to fluvoxamine, imipramine or...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-198907000-00006

    authors: Feighner JP,Boyer WF,Meredith CH,Hendrickson GG

    更新日期:1989-07-01 00:00:00

  • Quetiapine-induced myoclonus.

    abstract::We report a case of myoclonus induced by quetiapine. A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine. These movements were dose-related and completely abated on reducing the dose. To our knowledge, these movements have not been reported previously as an adverse effe...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200503000-00011

    authors: Velayudhan L,Kirchner V

    更新日期:2005-03-01 00:00:00

  • Clozapine-associated neutropenia in Latin America: incidence report of 5380 Chilean users.

    abstract::Systematic information about Latino clozapine users is still scarce. Our aim was to evaluate the risk of clozapine-associated neutropenia in a Chilean cohort using the last Food and Drug Administration's recommendations for clozapine monitoring. Findings should improve clinical practice and promote changes in clozapin...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000270

    authors: Mena CI,Nachar RA,Crossley NA,González-Valderrama AA

    更新日期:2019-09-01 00:00:00

  • Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine.

    abstract::Recent studies have shown that the use of subscales derived from the Hamilton Depression (HAM-D) rating scale are just as reliable and enhance sensitivity for detecting response and remission after antidepressant treatment. The purpose of the present study was to determine if the responses on two items of the HAM-D sc...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-200211000-00002

    authors: Silverstone PH,Entsuah R,Hackett D

    更新日期:2002-11-01 00:00:00

  • Use of perospirone for obesity and diabetes mellitus in patients with schizophrenia: three case reports.

    abstract::We report that perospirone may have had positive effects on the obesity of three patients with schizophrenia and on the fasting blood sugar (FBS) and HbA1C of two of them who had type 2 diabetes mellitus. ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-200401000-00008

    authors: Nishida M,Nakamura M

    更新日期:2004-01-01 00:00:00

  • Serotonin: current understanding and the way forward.

    abstract::Serotonin is a key neurotransmitter in the central nervous system. In recent years its role in the pathophysiology and pharmacology of depression has been extensively investigated. Neuroendocrine studies suggest decreased serotonergic responsivity in patients with major depression. The fact that the majority of patien...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Dinan TG

    更新日期:1996-03-01 00:00:00

  • Refining treatment approaches in obsessive-compulsive disorder.

    abstract::Obsessive-compulsive disorder (OCD) has emerged as a common but frequently hidden psychiatric disorder which inflicts an intolerable burden on sufferers and demands effective management. For many years, however, OCD was considered treatment resistant and it is only in the past 15 years that effective therapy has becom...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199612005-00003

    authors: Fineberg N

    更新日期:1996-12-01 00:00:00

  • Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as "new" drugs with established fluvoxamine?

    abstract::The tricyclic antidepressants (TCAs) are still considered as first-line treatment for depression, despite the availability of the selective serotonin reuptake inhibitors (SSRIs). This paper considers the current situation in reverse by assuming that only the SSRIs, in particular fluvoxamine, are available and the TCAs...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Ashford JJ

    更新日期:1995-01-01 00:00:00

  • The clock-drawing test as a possible indicator of acute psychosis.

    abstract::The clock-drawing test (CDT) is used widely to evaluate cognitive disorders, but its role in the assessment of psychotic disorders has not been studied. We sought to examine whether the CDT plays a role as an indicator of psychosis and to establish its sensitivity to clinical improvement of psychosis. The CDT was admi...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0000000000000118

    authors: Tene O,Sigler M,Shiloh R,Weizman A,Aizenberg D

    更新日期:2016-05-01 00:00:00

  • Carbamazepine in rapid cycling bipolar affective disorder.

    abstract::Eighteen patients with rapid cycling bipolar affective disorder were recruited for an open trial of carbamazepine. Of these patients all but 2 had been resistant to lithium prophylaxis. Twelve of the patients were able to complete at least 6 months on carbamazepine. Of these 12 patients, 2 had a complete remission of ...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-198804000-00003

    authors: Joyce PR

    更新日期:1988-04-01 00:00:00

  • Comorbidities in social phobia.

    abstract::In a sample of 2096 consecutive primary care patients recruited in the Paris region, social phobia was a highly prevalent disorder (5.1%). The most frequent comorbid condition was depressive episode, which affected 70% of patients with social phobia of early onset (at less than 15 years of age), while the highest asso...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/00004850-199710006-00004

    authors: Lecrubier Y,Weiller E

    更新日期:1997-10-01 00:00:00

  • Effects of venlafaxine extended release on resilience in posttraumatic stress disorder: an item analysis of the Connor-Davidson Resilience Scale.

    abstract::The aim was to evaluate the efficacy of venlafaxine extended release (ER) on characteristics of resilience, measured by the Connor-Davidson Resilience Scale, in patients with posttraumatic stress disorder (PTSD). Data were evaluated from a randomized, 6-month, international, multicenter study of adult outpatients with...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1097/YIC.0b013e32830c202d

    authors: Davidson J,Baldwin DS,Stein DJ,Pedersen R,Ahmed S,Musgnung J,Benattia I,Rothbaum BO

    更新日期:2008-09-01 00:00:00

  • Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients.

    abstract::The interaction between plasma concentrations of the tricyclic antidepressant amitriptyline and the metabolism of the new antipsychotic risperidone was studied in 12 patients with chronic schizophrenia. Each patient received 3 mg risperidone twice a day for 28 days. Amitriptyline was coadministered at doses of 50 mg/d...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-199705000-00004

    authors: Sommers DK,Snyman JR,van Wyk M,Blom MW,Huang ML,Levron JC

    更新日期:1997-05-01 00:00:00

  • Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis.

    abstract::The present study aimed to systematically compare overall loss to follow-up, discontinuation rates because of adverse events and discontinuation rates because of a lack of efficacy in published studies assessing the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs) compared to other second-g...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,meta分析

    doi:10.1097/00004850-200503000-00001

    authors: Gartlehner G,Hansen RA,Carey TS,Lohr KN,Gaynes BN,Randolph LC

    更新日期:2005-03-01 00:00:00

  • The relationship between social phobia and avoidant personality disorder: workshop report 3.

    abstract::Social phobia and avoidant personality disorder were new diagnoses in the third version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) and were considerably changed in the revised third version (DSM-III-R). A high rate of comorbidity between these disorders was observed, which can be explained ...

    journal_title:International clinical psychopharmacology

    pub_type:

    doi:

    authors: Dahl AA

    更新日期:1996-06-01 00:00:00

  • Comorbidity of panic and depression: implications for clinical management.

    abstract::Data from the National Comorbidity Survey (NCS) general population study and the World Health Organization (WHO) primary care study have established that comorbidity between panic and depression is one of the strongest psychiatric associations. The two studies agree that patients with panic-depression comorbidity have...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00004850-199804004-00003

    authors: Ballenger JC

    更新日期:1998-04-01 00:00:00

  • The effect of methylphenidate on anxiety and depression symptoms in patients with Asperger syndrome and comorbid attention deficit/hyperactivity disorder.

    abstract::The objective of this study was to assess the response of anxiety and depression symptoms to methylphenidate (MPH) treatment in patients with Asperger syndrome (AS) combined with attention deficit/hyperactivity disorder (ADHD). A group of 12 patients with AS/ADHD, aged 8-18 years, received 12 weeks of MPH treatment. T...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/YIC.0000000000000175

    authors: Golubchik P,Rapaport M,Weizman A

    更新日期:2017-09-01 00:00:00

  • Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.

    abstract::Recent evidence has demonstrated the efficacy of pegylated interferon-alpha (IFN-alpha) in treating hepatitis C virus infection. Neuropsychiatric complications commonly occur during the course of IFN treatment, with depressive symptoms usually appearing within the first 12 weeks. Few cases of the pegylated interferon-...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/01.yic.0000170263.46008.54

    authors: Sockalingam S,Balderson K

    更新日期:2005-09-01 00:00:00

  • Three-year follow-up of patients with panic disorder after short-term treatment with alprazolam and imipramine.

    abstract::Fifty-five patients with moderate to sever panic disorder were treated for 9 weeks with alprazolam or imipramine and were then, except for one patient who had committed suicide, re-examined after on average 3 years of treatment. At follow-up most patients (74%) did not suffer from panic attacks at all. In the beginnin...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199300820-00006

    authors: Lepola UM,Rimón RH,Riekkinen PJ

    更新日期:1993-07-01 00:00:00

  • Patient-based and clinician-based support for the remission criteria in schizophrenia.

    abstract::This analysis characterizes patients with schizophrenia or schizoaffective disorder treated with risperidone who met remission criteria. In a 50-week, open-label trial, stable patients received long-acting injectable risperidone every 2 weeks. Remission criteria included severity (absent-mild ratings on core symptoms ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/01.yic.0000224791.06159.88

    authors: Docherty JP,Bossie CA,Lachaux B,Bouhours P,Zhu Y,Lasser R,Gharabawi GM

    更新日期:2007-01-01 00:00:00

  • A clinical study of the selective MAO-A-inhibitor moclobemide (Ro 11-1163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion.

    abstract::A new selective MAO-A-inhibitor (noclobemide) was used in a double-blind comparative study of 23 patients with severe unipolar or bipolar depressive disorder. Two different doses of medication were given for 4 weeks. Effectiveness was measured by improvements in the Hamilton Rating Scale for Depression, a self-rating ...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-198704000-00011

    authors: Lensch K,Fuchs G,Böning J,Milech U

    更新日期:1987-04-01 00:00:00

  • Olanzapine-induced cerebral metabolic changes related to symptom improvement in schizophrenia.

    abstract::The pattern of brain metabolic changes produced by olanzapine has yet to be described, despite the theoretical and clinical interest of this new antipsychotic. We studied a group of 17 schizophrenic patients who underwent two fluoro-deoxyglucose-positron emission tomography (FDG-PET) studies under two different condit...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章

    doi:10.1097/00004850-200501000-00003

    authors: Molina V,Gispert JD,Reig S,Pascau J,Martínez R,Sanz J,Palomo T,Desco M

    更新日期:2005-01-01 00:00:00

  • Therapeutic receptor-blocking concentrations of neuroleptics.

    abstract::The therapeutic concentrations of antipsychotic drugs in the patient's plasma water or spinal fluid are identical to their blocking potencies in vitro at the dopamine D2 receptor, with the exception of clozapine which acts at D4. The variation in K values between laboratories stems from the fact that the apparent K va...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Seeman P

    更新日期:1995-09-01 00:00:00

  • Striking a balance between safety and efficacy: experience with the SSRI sertraline.

    abstract::Depression is a widespread and serious disorder inflicting an immeasurable toll on the lives of millions of people and affecting their families and colleagues. It is the cause of countless suicides especially in those whose illness has not been detected or given appropriate care. Until recently, effective pharmacother...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Casey DE

    更新日期:1994-06-01 00:00:00

  • Prescribing patterns of lithium or lithium+valproate in manic or mixed episodes: a naturalistic study.

    abstract::The present study aimed to identify the prescribing patterns of lithium or of lithium+valproate in 75 bipolar I outpatients in a manic or a mixed phase within a naturalistic setting. The differences between the two treatments and the correlation between serum lithium levels and response were also examined. The results...

    journal_title:International clinical psychopharmacology

    pub_type: 杂志文章

    doi:10.1097/YIC.0b013e3283642348

    authors: Muti M,Del Grande C,Musetti L,Marazziti D,Pergentini I,Corsi M,Turri M,Umberto Corsini G,Dell'Osso L

    更新日期:2013-11-01 00:00:00

  • A double-blind placebo-controlled trial of zopiclone 7.5 mg and temazepam 20 mg in insomnia.

    abstract::Zopiclone, a cyclopyrrolone with hypnotic properties was compared with temazepam and placebo in the treatment of insomnia. After a week's washout period, suitable subjects were allocated at random to zopiclone 7.5 mg or temazepam 20 mg or placebo for 2 weeks. Measurements of psychomotor function using the Leed's psych...

    journal_title:International clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00004850-199007000-00001

    authors: Ngen CC,Hassan R

    更新日期:1990-07-01 00:00:00